Overview Press Releases Events and Presentations Financials and Filings Stock Information Corporate Governance FAQs Email Alerts Madrigal press releases are available below. Search them by keyword or browse by date. Year None202420232022202120202019201820172016 April 3, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) March 18, 2024 Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering March 18, 2024 Madrigal Pharmaceuticals Announces Proposed Public Offering March 14, 2024 Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis March 6, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) March 5, 2024 Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis February 28, 2024 Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer February 28, 2024 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results February 21, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) February 8, 2024 Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine Pagination Previous page Page 1 Page 2 Current page 3 Page 4 Next page
Madrigal press releases are available below. Search them by keyword or browse by date. Year None202420232022202120202019201820172016 April 3, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) March 18, 2024 Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering March 18, 2024 Madrigal Pharmaceuticals Announces Proposed Public Offering March 14, 2024 Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis March 6, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) March 5, 2024 Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis February 28, 2024 Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer February 28, 2024 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results February 21, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) February 8, 2024 Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine Pagination Previous page Page 1 Page 2 Current page 3 Page 4 Next page
April 3, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 14, 2024 Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
March 6, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 5, 2024 Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
February 28, 2024 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
February 21, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 8, 2024 Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine
